Marshall Wace
CBAY

Marshall Wace’s Cymabay Therapeutics CBAY Stock Holding History

Marshall Wace’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-158,411
Closed -$2.36M – 2713
2023
Q3 		$2.36M Sell
158,411
-623,324
-80% -$8.26M ﹤0.01% 1151
2023
Q2 		$8.56M Buy
781,735
+538,554
+221% +$5.01M 0.02% 803
2023
Q1 		$2.12M Buy
243,181
+161,401
+197% +$1.29M ﹤0.01% 1423
2022
Q4 		$513K Buy
+81,780
New +$311K ﹤0.01% 2358
2022
Q3 		– Sell
-11,000
Closed -$33K – 3920
2022
Q2 		$33K Buy
+11,000
New +$26.3K ﹤0.01% 3345
2019
Q2 		– Sell
-63,589
Closed -$844K – 1951
2019
Q1 		$844K Buy
63,589
+9,231
+17% +$98.2K 0.01% 989
2018
Q4 		$428K Buy
+54,358
New +$517K ﹤0.01% 1158

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marshall Wace's CBAY Position: Q4 2023 in Review

Marshall Wace sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 158,411 shares — an estimated $2.36M sold.

Marshall Wace first reported a position in CBAY in Q4 2018 and held it in 7 quarters. The position peaked at $8.56M in Q2 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Marshall Wace reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Marshall Wace sold 158,411 Cymabay Therapeutics shares in Q4 2023, an estimated $2.36M.
  • Marshall Wace first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 7 quarters.
  • Marshall Wace's Cymabay Therapeutics position peaked at $8.56M in Q2 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Marshall Wace's 13F filing for Q4 2023, filed 14 Feb 2024.